Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen IncfiledCriticalImmunogen Inc
Priority to MYPI2019003152ApriorityCriticalpatent/MY203104A/en
Publication of MY203104ApublicationCriticalpatent/MY203104A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. (Fig.1)
OPTIONALLY SYNTAXED HETEROCYCL-SUBTITUTED PYRIMIDINE DERIVATIVES USEFUL FOR THE THERAPEUTIC TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES.